PHASE 3 testing of novel once-daily treatment IV-to-oral omadacycline from Paratek Pharmaceuticals has revealed that it effectively and safely treats the most frequently isolated bacterial pathogens associated with skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), according to a report in Dermatology Times.
Omadacycline is the first in a new class of tetracyclines, known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 May 17
